The company's programmable hypertension control (PHC) therapy is a patented cardiac pacing-based treatment for hypertension that can be incorporated into standard pacemakers using standard leads and lead placement. PHC offers a potent device-based HTN therapeutic alternative for HTN patients, particularly those who already have or require a pacemaker. Clinical results demonstrate that this therapy has a substantial and sustained therapeutic effect on blood pressure, with an average reduction of 24 mmHg from baseline in in-office cuff measurements and 14 mmHg from baseline in 24-hour ambulatory measurements. BackBeat's PHC therapy is protected by an extensive global patent portfolio.